Clinical trials · Washington, D.C., DC
Ependymoma clinical trials in Washington, D.C.
We’re tracking 8 recruiting ependymoma studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06193759RecruitingPhase 1
Immune cell therapy for malignant pediatric brain tumors
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Washington D.C., District of ColumbiaAges 1–30 - NCT07226453RecruitingPhase 2
Metformin for recurrent PFA ependymoma
This trial tests if metformin can help treat a certain type of brain tumor called PFA ependymoma that has come back after surgery and radiation. It's for people ages 1 to 39 who are healthy enough for surgery or have tumors that can be measured on scans.
Washington D.C., District of ColumbiaAges 1–39 - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
Washington D.C., District of ColumbiaAges 2–21 - NCT05057702Recruiting
Personalized surgery-focused treatment plan for relapsed brain cancer
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Washington D.C., District of ColumbiaAges 1–39 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT06161519RecruitingPhase 1/Phase 2
PLX038 for brain tumors with MYC or MYCN changes
This study tests a new drug called PLX038 for people with brain or spinal cord tumors that have certain genetic changes (MYC or MYCN) or have come back after treatment. The drug is given as an infusion and targets tumor cells. The study aims to see if the drug is safe and effective for different types of these tumors.
Bethesda, MarylandAges 18–120 - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04374305RecruitingPhase 2
Study tests targeted treatments for NF2 tumors
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
Baltimore, MarylandAges 12 years+
Hear when a new Ependymoma trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Ependymoma trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting ependymoma studies listed above.
- Children's National Medical Center · 5 studies
- National Institutes of Health Clinical Center · 2 studies
- Johns Hopkins Hospital
- Johns Hopkins University
What taking part in a ependymoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there ependymoma clinical trials near Washington, D.C.?
- Yes. We're currently tracking 8 recruiting ependymoma studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ependymoma study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ependymoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ependymoma studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.